Equillium, Inc. (EQ)
| Previous Close | 1.0600 |
| Open | 0.9500 |
| Bid | 0.8636 x 100 |
| Ask | 0.9621 x 100 |
| Day's Range | 0.8700 - 1.0300 |
| 52 Week Range | 0.4500 - 3.2500 |
| Volume | |
| Avg. Volume | 310,806 |
| Market Cap | 32.431M |
| Beta (5Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif., June 05, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on May 31, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement award consisting of a nonstatutory stock option to purchase 7,200 shares of common stock to a new employee under Equillium’s 2024 Inducement Plan. The Compensation Committee approve
- Business Wire
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
LA JOLLA, Calif., June 04, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline data from its Phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA), an autoimmune disease driven by an immune cell attack of the hair follicles that
- Business Wire
Equillium to Present at the Jefferies Global Healthcare Conference
LA JOLLA, Calif., May 29, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will present at the Jefferies Global Healthcare Conference taking place at the Marriott Marquis in New York, NY, June 4 – 6, 2024.
